243 related articles for article (PubMed ID: 32290128)
21. Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis.
Serrano-Martín X; Payares G; Mendoza-León A
Antimicrob Agents Chemother; 2006 Dec; 50(12):4214-6. PubMed ID: 17015627
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of the 7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline derivative against infection caused by Leishmania amazonensis.
Antinarelli LMR; Souza MVN; Coelho EAF; Lima WP; Coimbra ES
Rev Soc Bras Med Trop; 2020; 53():e20200091. PubMed ID: 32578713
[TBL] [Abstract][Full Text] [Related]
23. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
[TBL] [Abstract][Full Text] [Related]
24. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.
Schmidt-Ott R; Klenner T; Overath P; Aebischer T
Trans R Soc Trop Med Hyg; 1999; 93(1):85-90. PubMed ID: 10492799
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607026
[TBL] [Abstract][Full Text] [Related]
26. (-)-Epigallocatechin 3-
Inacio JDF; Fonseca MS; Almeida-Amaral EE
J Nat Prod; 2019 Sep; 82(9):2664-2667. PubMed ID: 31503486
[TBL] [Abstract][Full Text] [Related]
27. Chemical Characterization, Antileishmanial Activity, and Cytotoxicity Effects of the Essential Oil from Leaves of Pluchea carolinensis (Jacq.) G. Don. (Asteraceae).
García M; Scull R; Satyal P; Setzer WN; Monzote L
Phytother Res; 2017 Sep; 31(9):1419-1426. PubMed ID: 28703380
[TBL] [Abstract][Full Text] [Related]
28. Intramuscular and topical treatment of cutaneous leishmaniasis lesions in mice infected with Leishmania amazonensis using coumarin (-) mammea A/BB.
Tiuman TS; Brenzan MA; Ueda-Nakamura T; Filho BP; Cortez DA; Nakamura CV
Phytomedicine; 2012 Oct; 19(13):1196-9. PubMed ID: 22954418
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
[TBL] [Abstract][Full Text] [Related]
30. Activity of physalins purified from Physalis angulata in in vitro and in vivo models of cutaneous leishmaniasis.
Guimarães ET; Lima MS; Santos LA; Ribeiro IM; Tomassini TB; Ribeiro dos Santos R; dos Santos WL; Soares MB
J Antimicrob Chemother; 2009 Jul; 64(1):84-7. PubMed ID: 19454526
[TBL] [Abstract][Full Text] [Related]
31. Liposomal-lupane system as alternative chemotherapy against cutaneous leishmaniasis: macrophage as target cell.
Barros NB; Migliaccio V; Facundo VA; Ciancaglini P; Stábeli RG; Nicolete R; Silva-Jardim I
Exp Parasitol; 2013 Oct; 135(2):337-43. PubMed ID: 23933281
[TBL] [Abstract][Full Text] [Related]
32. In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis.
García Bustos MF; Barrio A; Prieto GG; de Raspi EM; Cimino RO; Cardozo RM; Parada LA; Yeo M; Soto J; Uncos DA; Parodi C; Basombrío MA
J Parasitol; 2014 Dec; 100(6):840-7. PubMed ID: 25014108
[TBL] [Abstract][Full Text] [Related]
33. A standardized intraperitoneal Glucantime™ for experimental treatment of cutaneous leishmaniasis caused by Leishmania amazonensis in BALB/c mice.
Brustolin AÁ; Franzói NM; Ramos-Milaré ÁCFH; Tanoshi CA; Mota CA; Demarchi IG; Lonardoni MVC; Verzignassi Silveira TG
Exp Parasitol; 2022; 236-237():108259. PubMed ID: 35427563
[TBL] [Abstract][Full Text] [Related]
34. A natural cell-penetrating nanopeptide combined with pentavalent antimonial as experimental therapy against cutaneous leishmaniasis.
Valentim Silva JR; de Barros NB; Aragão Macedo SR; Ferreira ADS; Moreira Dill LS; Zanchi FB; do Nascimento JR; Fernandes do Nascimento FR; Lourenzoni MR; de Azevedo Calderon L; Soares AM; Nicolete R
Exp Parasitol; 2020 Oct; 217():107934. PubMed ID: 32698075
[TBL] [Abstract][Full Text] [Related]
35. In silico and in vitro comparative activity of green tea components against Leishmania infantum.
Khademvatan S; Eskandari K; Hazrati-Tappeh K; Rahim F; Foroutan M; Yousefi E; Asadi N
J Glob Antimicrob Resist; 2019 Sep; 18():187-194. PubMed ID: 30797085
[TBL] [Abstract][Full Text] [Related]
36. Epimerization of tea catechins and O-methylated derivatives of (-)-epigallocatechin-3-O-gallate: relationship between epimerization and chemical structure.
Suzuki M; Sano M; Yoshida R; Degawa M; Miyase T; Maeda-Yamamoto M
J Agric Food Chem; 2003 Jan; 51(2):510-4. PubMed ID: 12517118
[TBL] [Abstract][Full Text] [Related]
37. The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis.
Gonçalves-Oliveira LF; Souza-Silva F; de Castro Côrtes LM; Veloso LB; Santini Pereira BA; Cysne-Finkelstein L; Lechuga GC; Bourguignon SC; Almeida-Souza F; da Silva Calabrese K; Ferreira VF; Alves CR
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():101-108. PubMed ID: 31430693
[TBL] [Abstract][Full Text] [Related]
38. An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis.
Lage LM; Barichello JM; Lage DP; Mendonça DV; Carvalho AM; Rodrigues MR; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Coelho EA; Duarte MC
Parasitol Res; 2016 Nov; 115(11):4083-4095. PubMed ID: 27365053
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
[TBL] [Abstract][Full Text] [Related]
40. Activity of hydroxyurea against Leishmania mexicana.
Martinez-Rojano H; Mancilla-Ramirez J; Quiñonez-Diaz L; Galindo-Sevilla N
Antimicrob Agents Chemother; 2008 Oct; 52(10):3642-7. PubMed ID: 18694950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
